Recent advances in the evaluation of systemic inflammatory responses using complete blood count–derived indices and C-reactive protein have opened new avenues for improving the diagnostic and prognostic assessment of testicular germ cell tumors. This evidence concerns the gene CRP and testicular germ cell tumor.